Kaiser Permanente Ventures

Kaiser Permanente Ventures (KPV) is the venture investment program of Kaiser Permanente, the Oakland-based integrated health system. KPV says it was founded more than 25 years ago and describes itself as one of the longest tenured strategic venture programs in healthcare. It invests in partnership with Kaiser Permanente and its limited partners, and its team includes Chris Grant of The Permanente Federation, the national organization of Kaiser's physician medical groups. KPV draws on Kaiser's scale, which it cites as more than 24,600 clinicians, 40 acute care hospitals and about $101 billion in annual operating revenue.

KPV reports about 70 investments to date. Its portfolio is organized into four categories: diagnostics and drug delivery, information technology, services, and therapeutics. Recent activity centers on healthcare technology and care delivery, with holdings including Abridge (generative AI clinical documentation), DexCare, NOCD, Vesta Healthcare, Arine, Garner Health, SureCo and Ordr, alongside earlier life sciences bets such as Freenome and Pulmonx. Disclosed rounds on its news page are typically Series A through Series C.

What sets KPV apart is access to a large care delivery organization as a source of insight and a test bed. The unit says it identifies the most pressing needs by working with the people who lead Kaiser's health systems and care delivery, then backs innovations that address them. Its track record includes Omada Health's June 2025 IPO, Health Catalyst's IPO, the acquisition of Collective Medical and NextHealth's sale to Softheon in 2022. Earlier investments in medical devices, diagnostics and specialty pharmaceuticals, such as Gynesonics, Oxford Immunotec and Agile Therapeutics, reflect the program's broader life sciences history.